Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MAGEA4 is a member of the MAGEA gene family. Additionally we are shipping MAGEA4 Proteins (9) and many more products for this protein.
Showing 10 out of 82 products:
Human Polyclonal MAGEA4 Primary Antibody for IHC (p), WB - ABIN390108
Nagao, Higashitsuji, Nonoguchi, Sakurai, Dawson, Mayer, Itoh, Fujita: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. in The Journal of biological chemistry 2003
Show all 2 Pubmed References
Human Monoclonal MAGEA4 Primary Antibody for IF, ELISA - ABIN517692
Kawada, Wada, Isobe, Gnjatic, Nishikawa, Jungbluth, Okazaki, Uenaka, Nakamura, Fujiwara, Mizuno, Saika, Ritter, Yamasaki, Miyata, Ritter, Murphy, Venhaus, Pan, Old, Doki, Nakayama: Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. in International journal of cancer. Journal international du cancer 2011
a cleaved form of MAGE-A4 binds to Miz-1 (show ZBTB17 Antibodies) and induces apoptosis
Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC (show CALR Antibodies)) and advanced adenoma.
High MAGE-A4 expression is associated with Lung Cancer.
Results found concomitant overexpression of MAGEA4 and TWIST1 (show TWIST1 Antibodies) in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 (show TWIST1 Antibodies) expression, which was found as indirect binding of TWIST1 (show TWIST1 Antibodies) to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1 (show TWIST1 Antibodies).
Results support the potential utility of NY-ESO-1 (show CTAG1B Antibodies), PRAME (show PRAME Antibodies), and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.
Data show that overall survival (OS) was significantly lower for patients expressing pan (show SUPT6H Antibodies)-MAGE (show MAGEB10 Antibodies) or MAGE (show MAGEB10 Antibodies)-A1/A3/A4 in both independent cohorts.
the crystal structures of MAGE-A3 (show MAGEA3 Antibodies) and MAGE-A4
CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors.
HLA class I (show MICA Antibodies) loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer .
Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer.
Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. At least four variants encoding the same protein have been found for this gene.
melanoma antigen family A, 4
, MAGE-4 antigen
, MAGE-41 antigen
, MAGE-X2 antigen
, cancer/testis antigen 1.4
, cancer/testis antigen family 1, member 4
, melanoma-associated antigen 4